Cytokine Signalling Forum


Tocilizumab tedavisi sırasında oluşan majör kardiyovasküler advers olaylar için risk faktörlerinin değerlendirilmesi

Rao VU, Pavlov A, Klearman M, Musselman D, Giles JT, Bathon JM, Sattar N, Lee JS. - Arthritis Rheumatol. 2015;67(2):372–380

The risk of cardiovascular (CV) disease among RA patients, compared with the general population is well documented. Alongside this, studies have been able to establish that risk factors in RA patients are not wholly associated with traditional CV risk factors such as such as diabetes mellitus, hypertension, smoking, and dyslipidemia, suggesting a relationship between parameters of RA disease activity and increased CV risk. Additionally, IL-6 has been linked with the development of coronary heart disease both in patients with RA and in the general population.

These retrospective post hoc analyses explore associations of baseline and on-treatment lipid levels, inflammation, and RA disease activity with risk for major adverse CV events (MACE) in tocilizumab (anti–IL-6 mAb)-treated RA patients. Data were pooled from 3986 adults with moderate to severe RA administered =1 dose of tocilizumab 4 or 8 mg/kg intravenously every 4 weeks in randomized controlled trials and extension studies. MACE was defined as definite or probable nonfatal MI, nonfatal stroke, or death from a CV cause. An association was observed between baseline total cholesterol/high-density lipoprotein ratio and increased risk for MACE, as in the general population. Risk for on-treatment MACE, however, was found to be associated with control of disease activity but not lipid changes. This analysis suggests that changes in measures of RA disease activity, but not necessarily lipid changes, are associated with incident MACE in tocilizumab-treated patients.

Keywords: IL-6, Tocilizumab, Cardiovascular

Access original article via Pubmed

Upload date: December 2014

Translated by: Ege Sinan TORUN

Article image